{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:17:21Z","timestamp":1747167441544,"version":"3.40.5"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.meegid.2018.02.016","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T12:02:15Z","timestamp":1518523335000},"page":"42-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-9694","authenticated-orcid":false,"given":"Jessica","family":"Cusato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amedeo","family":"De Nicol\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Boglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Favata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ariaudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Mornese Pinna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Carcieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Guido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Avataneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cariti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D'Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.meegid.2018.02.016_bb0005","unstructured":"(EMA) EMA 2014 Sovaldi summary of product characteristics. Edited by Editor|. Year|; p.^pp. Pages|. City|: Publisher|."},{"key":"10.1016\/j.meegid.2018.02.016_bb0010","unstructured":"(FDA) FaDA 2014a. Pharmacology review. NDA:205834. Edited by Editor|. Year|; p.^pp. Pages|. City|: Publisher|."},{"key":"10.1016\/j.meegid.2018.02.016_bb0015","unstructured":"(FDA) FaDA 2014b. Chemistry review. NDA:205834. Edited by Editor|. Year|; p.^pp. Pages|. City|: Publisher|."},{"key":"10.1016\/j.meegid.2018.02.016_bb0020","unstructured":"(FDA) FaDA 2014c. Clinical pharmacology and biopharmaceutics review. NDA: 203854. Edited by Editor|. Year|; p.^pp. Pages|. City|: Publisher|."},{"key":"10.1016\/j.meegid.2018.02.016_bb0025","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1359\/jbmr.2001.16.7.1256","article-title":"The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene","volume":"16","author":"Arai","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.meegid.2018.02.016_bb0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpba.2016.04.031","article-title":"A UHPLC-MS\/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir\/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma","volume":"125","author":"Ariaudo","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.meegid.2018.02.016_bb0035","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jvh.12288","article-title":"Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon","volume":"22","author":"Boglione","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.meegid.2018.02.016_bb0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/17425255.2017.1255725","article-title":"Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C","volume":"13","author":"Cuenca-Lopez","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.meegid.2018.02.016_bb0045","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3851\/IMP2853","article-title":"Vitamin D pathway gene variants and HCV-2\/3 therapy outcomes","volume":"20","author":"Cusato","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.meegid.2018.02.016_bb0050","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/FPC.0000000000000123","article-title":"VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia","volume":"25","author":"Cusato","year":"2015","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.meegid.2018.02.016_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biopha.2014.11.007","article-title":"ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy","volume":"69","author":"Cusato","year":"2015","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.meegid.2018.02.016_bb0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.18433\/J3DK6T","article-title":"Intracellular and plasma trough concentration and pharmacogenetics of Telaprevir","volume":"18","author":"Cusato","year":"2015","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.meegid.2018.02.016_bb0065","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ijantimicag.2015.01.019","article-title":"Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics","volume":"45","author":"Cusato","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.meegid.2018.02.016_bb0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/FPC.0000000000000223","article-title":"Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia","volume":"26","author":"Cusato","year":"2016","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.meegid.2018.02.016_bb0075","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/hep.24636","article-title":"Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon\/ribavirin treatment in patients infected with hepatitis C virus genotype 1\/4","volume":"54","author":"D'Avolio","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2018.02.016_bb0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/FTD.0b013e31824bf778","article-title":"Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment","volume":"34","author":"D'Avolio","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.meegid.2018.02.016_bb0085","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/FTD.0b013e318272e55a","article-title":"Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG\/IFN-RBV treatment","volume":"34","author":"D'Avolio","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.meegid.2018.02.016_bb0090","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.antiviral.2013.07.021","article-title":"Association of ITPA polymorphisms rs6051702\/rs1127354 instead of rs7270101\/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients","volume":"100","author":"D'Avolio","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.meegid.2018.02.016_bb0095","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2217\/pgs.16.22","article-title":"Pharmacogenetics of ribavirin-induced anemia in HCV patients","volume":"17","author":"D'Avolio","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.meegid.2018.02.016_bb0100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijpharm.2015.11.044","article-title":"Ethambutol plasma and intracellular pharmacokinetics: a pharmacogenetic study","volume":"497","author":"Fatiguso","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.meegid.2018.02.016_bb0105","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3748\/wjg.v22.i4.1421","article-title":"New approaches in the treatment of hepatitis C","volume":"22","author":"Gonz\u00e1lez-Grande","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.meegid.2018.02.016_bb0110","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/lt.24126","article-title":"Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients","volume":"21","author":"Gutierrez","year":"2015","journal-title":"Liver Transpl."},{"key":"10.1016\/j.meegid.2018.02.016_bb0115","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrendo.2010.226","article-title":"Antibacterial effects of vitamin D","volume":"7","author":"Hewison","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.meegid.2018.02.016_bb0120","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2018.02.016_bb0125","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1998.78.4.1193","article-title":"Current understanding of the molecular actions of vitamin D","volume":"78","author":"Jones","year":"1998","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.meegid.2018.02.016_bb0130","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-014-0142-5","article-title":"Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations","volume":"53","author":"de Kanter","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.meegid.2018.02.016_bb0135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3892\/ijo.2013.2204","article-title":"Vitamin D receptor gene polymorphisms in breast and renal cancer: current state and future approaches (review)","volume":"44","author":"Khan","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.meegid.2018.02.016_bb0140","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJMc1307641","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"369","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2018.02.016_bb0145","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/hepr.12867","article-title":"ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin","volume":"47","author":"Murakawa","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.meegid.2018.02.016_bb0150","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1210\/jc.2006-0678","article-title":"Immune regulation of 25-hydroxyvitamin D-1alpha-hydroxylase in human monocytic THP1 cells: mechanisms of interferon-gamma-mediated induction","volume":"91","author":"Overbergh","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.meegid.2018.02.016_bb0155","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/FPC.0b013e328354455c","article-title":"Very important pharmacogene summary for VDR","volume":"22","author":"Poon","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.meegid.2018.02.016_bb0160","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2018.02.016_bb0165","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1101\/gr.107920.110","article-title":"A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution","volume":"20","author":"Ramagopalan","year":"2010","journal-title":"Genome Res."},{"key":"10.1016\/j.meegid.2018.02.016_bb0170","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jsbmb.2006.12.056","article-title":"CYP2R1-, CYP27B1- and CYP24-mRNA expression in German type 1 diabetes patients","volume":"103","author":"Ramos-Lopez","year":"2007","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.meegid.2018.02.016_bb0175","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bcp.2008.05.030","article-title":"Identification of the functional vitamin D response elements in the human MDR1 gene","volume":"76","author":"Saeki","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.meegid.2018.02.016_bb0180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2015.07.011","article-title":"Effect of IL28B genotype on hepatitis B and C virus infection","volume":"14","author":"Stattermayer","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.meegid.2018.02.016_bb0185","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/liv.12106","article-title":"Vitamin D in chronic liver disease","volume":"33","author":"Stokes","year":"2013","journal-title":"Liver Int."},{"key":"10.1016\/j.meegid.2018.02.016_bb0190","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.3748\/wjg.v19.i35.5917","article-title":"Association between vitamin D and hepatitis C virus infection: a meta-analysis","volume":"19","author":"Villar","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.meegid.2018.02.016_bb0195","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0140-6736(10)60588-0","article-title":"Common genetic determinants of vitamin D insufficiency: a genome-wide association study","volume":"376","author":"Wang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2018.02.016_bb0200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11154-011-9195-z","article-title":"Vitamin D metabolism and signaling in the immune system","volume":"13","author":"White","year":"2011","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.meegid.2018.02.016_bb0205","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2018.02.016_bb0210","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1365-2265.2008.03413.x","article-title":"Vitamin D receptor (VDR) gene polymorphisms and Graves' disease: a meta-analysis","volume":"70","author":"Zhou","year":"2009","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.meegid.2018.02.016_bb0215","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/oxfordjournals.epirev.a018033","article-title":"Molecular epidemiology of vitamin D receptor gene variants","volume":"22","author":"Zmuda","year":"2000","journal-title":"Epidemiol. Rev."}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134818300613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134818300613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T23:33:47Z","timestamp":1535067227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134818300613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":43,"alternative-id":["S1567134818300613"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2018.02.016","relation":{},"ISSN":["1567-1348"],"issn-type":[{"type":"print","value":"1567-1348"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2018.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}